Sanofi makes low-cost medicines pledge for low-income countries
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a […]
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a […]
June 7, 2022, Washington DC – Fishawack Health (FH) announces the acquisition of leading healthcare consulting and advisory firm Avalere Health (Avalere) from Inovalon, which […]
US pharma giant Pfizer has said it will sell some of its patented medicines at non-profit prices to 45 of the world’s poorest countries – […]
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling […]
March 3, 2022, London, UK—Fishawack Health (FH), a leading commercialization partner for biopharmaceutical, medical technology, and wellness companies, today welcomes the US-based health economics and […]
In its second report evaluating where hospitals are with complying with the price transparency rule that went into effect Jan. 1, 2021, PatientRightsAdvocate.org found compliance […]
The UK Competition and Markets Authority has ruled that several drugmakers worked together to raise the NHS price of widely-used nausea drug prochlorperazine, fining them […]
Mark Cuban, billionaire owner of the Dallas Mavericks basketball team, just got involved in the online pharmacy business, promising to “shield consumers from inflated drug […]
The man who sent the price of lifesaving drug Daraprim (pyrimethamine) rocketing from $13.50 a tablet to $750 overnight has been ordered to repay $64.6m […]
AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on […]
With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Economic Review (ICER) has published its third […]
Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to […]
The US government has sold off the one-of-a-kind Wu-Tang Clan album famously bought by ‘pharma bro’ Martin Shkreli, with the proceeds enough to wipe out […]
The US government has sold off the one-of-a-kind Wu-Tang Clan album famously bought by ‘pharma bro’ Martin Shkreli, with the proceeds enough to wipe out […]
The UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to several pharma companies accused of colluding to […]
The US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm will be covered by Medicare, to see […]
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on […]
The Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm when it issued its first report on […]
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will be held on the 28th – 29th of June, 2021 at the BGS online platform. CIOs and […]
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
On Wednesday, April 28th, the World Orphan Drug Congress USA is being held online for free! The conference brings together pharma, biotechs, government, payers, investors […]
Italy was working up big changes in market access throughout 2020 which will be implemented in 2021. In the latest of a suite of features […]
Bureaucracy, political upheaval, and lack of regulations continue to make Latin America a difficult market for European and North American pharma to enter – and […]
The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo […]
Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is the third […]
Copyright © 2024 | WordPress Theme by MH Themes